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Investment Opportunities In Biotechnology: 
Prospects and Strategies 
ARTHUR R. KYDD 
Arthur R. Kydd is a Managing General Partner for St. Croix Venture Funds. 
Biotechnology - The Prospects 
The biotechnology industry got its start about a dozen years 
ago when, for the first time, a gene was moved from one living 
organism to another. What followed from this early gene 
transfer experimentation was a technological revolution and 
the formation of many biotechnology companies- along with 
the prospects of exciting opportunities for investors. 
It wasn't realized then, but today we know with certainty, 
that biotechnology will indeed have a most profound impact 
on our lives, affecting a broad cross section of our economy, 
from agriculture to energy, chemicals and medicine, and to 
almost every type of consumer or industrial product we can 
imagine. . 
The most visible areas of application have been, and partic-
ularly in the future will be, in the human healthcare field, 
where biotechnology provides a very powerful means for the 
generation of new diagnostic tests and therapeutic sub-
stances. Biotechnology holds the promise of eliminating 
AIDS, and of killing off the stubbornly resistant cancers. We 
may be able to develop vaccines for just about any disease-
and these prospects are very exciting. 
As part of this technological revolution, in just the past 10 
years, 150 companies were started and billions of dollars were 
invested to develop and produce "biotechnology" products. 
Today, many of these companies are coming of age and 
biotechnology is being transformed from a research and pro-
duct development phase to a sales and marketing mode. 
Although biotechnology product sales are still quite mo_d-
est today, they are increasing dramatically, and the prospects 
for future biotechnology product sales are spectacular. For 
example, the market for human growth hormone is projected 
at $50 million in annual sales; human insulin is projected at 
$125 million per year; interleukin-2 at $400 million; and tissue 
plasminogen activator at a billion dollars per year. The~e 
therapeutic product sales levels may be reached by the m1d 
1990s. 
Production of human diagnostics and therapeutics by bio-
technology is expected to be a multi-billion dollar industry by 
the year 2000. In chemicals and drugs, annual sales of pro-
ducts produced by gene splicing may be many more billions 
of dollars by then. In agriculture, genetically engineered seed 
for new plant varieties, as well as other plant and animal 
biotechnology applications, could produce billions of dollars 
in annual business. We may guess incorrectly about some of 
these markets, but the whole of biotechnology is expected to 
be more than a $100 billion industry by the year 2000. 
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Product innovation seems always to be the domain of the 
small company. Today, however, after 10 years of research, 
development, and product incubation, biotechnology pro-
duct sales from all of these start-up companies are a small 
fraction of the sales of the giant pharmaceutical and drug 
companies. And surprisingly, only a few of thse young bi~­
technology companies have failed. They have been well capi-
talized, and have been supported by the large pharmaceutical 
companies through corporate partner research contracts and 
other agreements as well as through equity capital provided 
by these large companies. Although the big companies h.a~e 
been doing a lot of biotechnology research themselves, 1t ts 
expeditious for them to acquire an equity position in a smaller 
company to obtain a window on technology, or, in some 
instances, to simply acquire some of these "start-ups" fortheir 
technologies and potential. 
Eli Lilly bought Hybritech for more than $400 million in 
stock and warrants, and Bristol-Myers picked up Genetic Sys-
tems for nearly $300 million in a stock swap. Even the small 
biotechnology companies are being acquired; for example, 
Pandex Laboratories, a promising diagnostic instrumentation 
company in Chicago, was acquired for approximately $30 
million in cash by Baxter Travenol. It is clear that these large 
pharmaceutical companies see something in the biotechn~l ­
ogy values of these smaller companies that is not reflected m 
the amount of their product sales. 
The prospects for these biotechnology companies appear 
to be very bright. Should we, therefore, be buyers of the 
common shares of these companies? 
The Value of Biotechnology 
The values of these start-up biotechnology companies 
appear to be extremely high as suggested by the stock p:i~es 
of some of the publicly traded companies, or by the aquts1t1on 
prices paid, or by the pricing of equity positions taken by large 
companies. These values may also reflect the market expecta-
tion for biotechnology companies in the future. 
The market valuation of all these small biotechnology 
companies is about $9 billion, with the 10 largest publicly 
traded biotechnology companies representing about $7 bil-
lion of this and Genentech having about $3 billion of the $7 
billion. The market valuation of the pharmaceutical compan-
ies in contrast is about $200 billion. However, the values for 
the large pharmaceutical and drug companies are reflected by 
product sales, normal price/ earnings ratios and.other invest-
ment criteria we would like to see for the new biotechnology 
companies. 
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If we believe, as many of us do, that the industtywill indeed 
realize significant future sales of biotechnology products, we 
can then place a future value on these biotechnology compan-
ies in the conventional way in which we evaluate any industty 
group, such as the major pharmaceutical and drug sectors. We 
assume that not all future biotechnology product sales will be 
by these up-start start-ups-perhaps 50% would be a fair 
estimate. The balance of biotechnology product sales would 
be by the multi-national pharmaceutical and drug companies. 
Remember also that these large companies are acquiring, or 
investing in, these small biotechnology companies. 
Another point should be made. Although new biotechnol-
ogy companies will continue to start-up to exploit niche 
markets and specific product opportunity areas, the main-
stream of biotechnology companies will already have been 
established in the markets and new entries will be few. It is 
expected that fully 2/ 3 of the companies presently in business 
today will be gone in 10 years-some will fail , many will be 
acquired by others. As a result, a smaller number of companies 
will cut up the biotechnology pie in the future markets. 
The market value of the biotechnology companies (today 
$9 billion) may possibly be $100 bill ion in the year 2000- but 
divided among considerably fewer players. Assuming 50 bio-
technology companies remain at that time, the average market 
value of each company would be $2 billion-a 20-fold 
increase over the average market value today. 
Investment Strategies 
Before reaching for your checkbook to make an investment 
in biotechnology today, understand that any number of 
assumptions can be made and any number of differing results 
may be suggested. An investment today in evety one of the 
biotechnology companies held until the year 2000, quite 
assuredly will not realize the 20-fold average increase sug-
gested above. Even if the industty values came true in that 
year, dilution of the investment interests by the significant 
additions to equity capital that may be necessary along the way 
would change the returns. And how much is won or lost in 
those companies that are acquired or go out of business is 
anyone's guess. 
The hint of signficant values in biotechnology, however, is 
realistic. It may require considerable patience, some anguish, 
and a lot of luck, however, to realize your investment return 
dream in biotechnology. 
The typical investment strategies can be suggested. This 
assumes considerable diligence on your part, a lot of sound 
advice from others, and a long-term investment posture. 
Invest in those undervalued biotechnology companies that 
have significant technologies and markets, excellent man-
agement, considerable capital, several corporate partner rela-
tionships, and various sales and marketing agreements that 
will result in significant growth in sales and earnings. 
Investment Opportunities in U.S. 
Biotechnology Companies - High Upside 
Rewards Hand-in-Hand with Equally 
Great Downside Risk 
EDWARD L. MUfSCH 
Edward L. Mutscb is a Managing Director and Healtbcare Industry Analyst at Piper, jaffrey, & Hopwood Incorporated 
Until comparatively recently, biotechnology has been a 
subject of intense interest to a relatively narrow audience, 
namely, to that segment of the scientific community working 
at the leading edge of this "new biology." While there has 
been a growing amount of communication in the lay press of 
the progress and implications of biotechnology, attempts to 
convey the significance of recombinant DNA, monoclonal 
antibodies, hybridoma cells, and DNA probes have been a bit 
bewildering to the general reader. This bewilderment has 
only been compounded by discussions of high-potential new 
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products with esoteric sounding names and strange sets of 
initials ; e.g. , tissue plasminogen activator (TPA) , tissue necro-
sis factor (TNF), colony stimulating factor ( CSF), epidermal 
growth factor (EGF), angiogenesis inhibitor, and Factor VIII, 
being pursued by a great number of new companies with 
confusingly similar names such as Genentech, Genex, Inte-
grated Genetics, Plant Genetics, Molecular Genetics, Biogen, 
Amgen, and Calgene. Excitement has nonetheless grown as 
the potential to employ this technology and these substances 
to treat diseases such as cancer, AIDS, and cardiovascular 
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